116 related articles for article (PubMed ID: 9235735)
1. [Campath-1H--a monoclonal antibody for treatment of non-Hodgkin's and chronic lymphatic leukemia].
de Nully Brown P; Hansen MM; Nissen NI
Ugeskr Laeger; 1997 Jul; 159(28):4389-93. PubMed ID: 9235735
[TBL] [Abstract][Full Text] [Related]
2. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
Osterborg A; Dyer MJ; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H
J Clin Oncol; 1997 Apr; 15(4):1567-74. PubMed ID: 9193354
[TBL] [Abstract][Full Text] [Related]
3. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
Lundin J; Osterborg A; Brittinger G; Crowther D; Dombret H; Engert A; Epenetos A; Gisselbrecht C; Huhn D; Jaeger U; Thomas J; Marcus R; Nissen N; Poynton C; Rankin E; Stahel R; Uppenkamp M; Willemze R; Mellstedt H
J Clin Oncol; 1998 Oct; 16(10):3257-63. PubMed ID: 9779699
[TBL] [Abstract][Full Text] [Related]
4. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.
Pangalis GA; Dimopoulou MN; Angelopoulou MK; Tsekouras C; Vassilakopoulos TP; Vaiopoulos G; Siakantaris MP
Med Oncol; 2001; 18(2):99-107. PubMed ID: 11778765
[TBL] [Abstract][Full Text] [Related]
5. Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).
Osterborg A; Werner A; Halapi E; Lundin J; Harmenberg U; Wigzell H; Mellstedt H
Eur J Haematol; 1997 Jan; 58(1):5-13. PubMed ID: 9020367
[TBL] [Abstract][Full Text] [Related]
6. Campath-1H.
Sorokin P
Clin J Oncol Nurs; 2001; 5(2):65-6. PubMed ID: 11899778
[TBL] [Abstract][Full Text] [Related]
7. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
Dumont FJ
Expert Rev Anticancer Ther; 2002 Feb; 2(1):23-35. PubMed ID: 12113063
[TBL] [Abstract][Full Text] [Related]
8. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
[TBL] [Abstract][Full Text] [Related]
9. Campath-1H monoclonal antibody therapy.
Flynn JM; Byrd JC
Curr Opin Oncol; 2000 Nov; 12(6):574-81. PubMed ID: 11085457
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
[TBL] [Abstract][Full Text] [Related]
11. Campath-1H in B-chronic lymphocytic leukemia: report on a patient treated thrice in a 3 year period.
Pangalis GA; Dimopoulou MN; Angelopoulou MK; Tsekouras CH; Siakantaris MP
Med Oncol; 2000 Feb; 17(1):70-3. PubMed ID: 10713664
[TBL] [Abstract][Full Text] [Related]
12. Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection.
Heider U; Fleissner C; Zavrski I; Jakob C; Dietzel T; Eucker J; Ockenga J; Possinger K; Sezer O
Eur J Haematol; 2004 Jan; 72(1):64-6. PubMed ID: 14962266
[TBL] [Abstract][Full Text] [Related]
13. In vivo 'purging' of residual disease in CLL with Campath-1H.
Dyer MJ; Kelsey SM; Mackay HJ; Emmett E; Thornton P; Hale G; Waldmann H; Newland AC; Catovsky D
Br J Haematol; 1997 Jun; 97(3):669-72. PubMed ID: 9207420
[TBL] [Abstract][Full Text] [Related]
14. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
Pawson R; Dyer MJ; Barge R; Matutes E; Thornton PD; Emmett E; Kluin-Nelemans JC; Fibbe WE; Willemze R; Catovsky D
J Clin Oncol; 1997 Jul; 15(7):2667-72. PubMed ID: 9215839
[TBL] [Abstract][Full Text] [Related]
15. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies.
Dyer MJ
Semin Oncol; 1999 Oct; 26(5 Suppl 14):52-7. PubMed ID: 10561018
[TBL] [Abstract][Full Text] [Related]
16. Treatment with campath-1H for relapsed chronic lymphocytic leukemia after allogeneic peripheral blood stem cell transplantation does not abrogate the development of chronic GVHD.
Wolff D; Steiner B; Stilgenbauer S; Kahl C; Leithäuser M; Junghanss C; Wilhelm S; Kleine HD; Zimmermann R; Hartung G; Casper J; Freund M
Eur J Haematol; 2004 Feb; 72(2):145-8. PubMed ID: 14962253
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia.
Bowen AL; Zomas A; Emmett E; Matutes E; Dyer MJ; Catovsky D
Br J Haematol; 1997 Mar; 96(3):617-9. PubMed ID: 9054672
[TBL] [Abstract][Full Text] [Related]
18. A personal history of the CAMPATH-1H antibody.
Waldmann H
Med Oncol; 2002; 19 Suppl():S3-9. PubMed ID: 12180490
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H).
Ru X; Liebman HA
Br J Haematol; 2003 Oct; 123(2):278-81. PubMed ID: 14531909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]